Aerie Pharmaceuticals, Inc. AERI reported mixed results for the fourth quarter of 2019, following which shares have been up in after-market trading.
Notably, Aerie’s stock has slumped 50.3% in the past year compared with the
industry’s decline of 3.4%.
The company reported a loss of 96 cents per share in fourth-quarter 2019, wider than the Zacks Consensus Estimate of a loss of 75 cents. The loss in the year-ago quarter was 92 cents per share.
The company’s first drug Rhopressa (netarsudil ophthalmic solution) has been approved for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Aerie’s second drug, Rocklatan, a once-daily, quadruple-action, fixed-dose combination of Rhopressa and Pfizer’s
PFE Xalatan, has been approved to reduce elevated IOP in patients with open-angle glaucoma or ocular hypertension.
Sales from both drugs came in at $24.6 million in the reported quarter, beating the Zacks Consensus Estimate of $20 million and higher than the year-ago quarter’s $14.5 million. Sequentially, revenues were up from $18.5 million in the previous quarter.
Quarter in Detail
Total operating expenses (excluding stock-based compensation expenses) in the quarter were $61.7 million, flaring up from the year-ago quarter’s $56.3 million.
Loss per share came in at $3.40 in 2019 compared with the prior year’s $4.65. Sales came in at $69.9 million, up from the $24.2 million generated in 2018.
Aerie acquired Avizorex Pharma S.L. (Avizorex), a Spanish ophthalmic pharmaceutical company, developing therapeutics for the treatment of dry eye disease. Avizorex completed a phase IIa study in dry eye subjects in 2019 with its lead product candidate AVX-012. Aerie plans to initiate a larger phase IIb study in late 2020.
Aerie’s retina program, evaluating AR-13503 (Rho kinase and Protein kinase C inhibitor implant) and AR-1105 (dexamethasone steroid implant), continues to advance as well. In March 2019, a phase II study was initiated on AR-1105 for macular edema due to retinal vein occlusion and the study is fully enrolled ahead of schedule. Top-line data from the study is expected this year. A study on AR-13503 (Rho kinase and Protein kinase C inhibitor implant) commenced last August for wet age-related macular degeneration and diabetic macular edema.
The European Commission granted a marketing authorisation to Rhokiinsa 0.02%. The European Medicines Agency (EMA) has accepted for review the marketing authorisation application (MAA) for Roclanda. An opinion from the EMA’s Committee for Medicinal Products for Human Use on the same is expected in late 2020. Top-line data from the Mercury 3 phase III study in Europe is expected in the second half of this year.
The company expects full-year 2020 net revenues in the range of $100 million to $110 million.
While results for the December-end quarter were mixed, the guidance for 2020 looks encouraging. The volumes picked up in the last two months of 2019. However, competition will be stiff from the likes of Allergan’s
AGN Lumigan and Bausch Health's ( BHC Quick Quote BHC - Free Report) Vyzulta in 2020, among others. Zacks Rank
Aerie currently carries a Zacks Rank #2 (Buy). You can see
the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>